Clinical Trial

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical efficacy remains limited. Previous studies by our team have found that methotrexate can activate anti-tumor immunity. The discovery of a new effect of this drug will improve tumor response to immunotherapy and prognosis of patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-08-30; most recent amendment 2024-10-22.
Status change: Recruiting → Active, Not Recruiting 2024-10-22
Trial Details
NCT Number NCT05522582
Lead Sponsor Yancheng First People's Hospital
Conditions Solid Tumors
Enrollment 50 participants
Start Date 2021-11-15
Primary Completion 2023-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-26